At F-star, we are committed to delivering life-changing treatments to cancer patients. We develop mAb², a novel class of disruptive bispecific antibody-based therapy that have the potential to overcome tumour resistance and restore anti-cancer immunity and responsiveness.
F-star is a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific antibody (mAb²™) format, F-star’s mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability.
F-star’s laboratory team is based in Cambridge-UK with an expanding footprint in the US to support our clinical stage pipeline.
Reporting to the VP, CMC, the Associate Director/Director CMC is a proactive, hands-on scientific leader with a strong technical background in late-stage CMC for biologics. They will play a key role in scientific direction setting and technical oversight for outsourced Drug Substance & Drug Product CMC development and manufacture in support of clinical development of multiple F-star mAb2 clinical programmes, to eventual commercial registration. This role will work closely with VP, CMC as a pivotal member of CMC leadership and across the Organisation including Quality Assurance, Regulatory Affairs, Clinical Operations.